您要查找的是不是：
- Rosiglitazone Malcate 马来酸罗格列酮
- This problem was not seen in men taking rosiglitazone. 在罗格列酮组男性患者中，没有观察到骨折发生率的增加。
- Groups of 2DM, IGR were recepted rosiglitazone 4 mg/day for three month. IGR和2DM组接受3个月罗格列酮治疗。
- To observe the effects of Rosiglitazone on endothelial function in ASO patients. 观察罗格列酮对ASO患者外周血管内皮功能的影响。
- Avandia is known generically as rosiglitazone, while Actos is known as pioglitazone. 文迪雅的通用名为罗格列酮，艾可拓通用名为吡格列酮。
- In these trials, 15 560 patients were assigned to rosiglitazone and 12 283 received placebo or an active comparator. 在这些试验中，15560名受试者被分配到罗格列酮组，12283接受安慰剂或活性对比药物组。
- The insulin-sensitising drug rosiglitazone enhanced protection afforded by low levels of insulin, the study showed. 研究显示，提高胰岛素敏感性的药物罗格列酮增强了低水平胰岛素下蛋白质的耐受性。
- The effect of rhein in lipidemia and mitochondrial of renal tubular epithelia was more strong than rosiglitazone. 大黄酸对脂代谢紊乱及肾小管线粒体的作用明显优于罗格列酮。
- In these trials, 15 560 patients were assigned to rosiglitazone and 12 283 receied placebo or an actie comparator. 在这些试验中，15560名受试者被分配到罗格列酮组，12283接受安慰剂或活性对比药物组。
- Recent meta-analysis have further suggested that rosiglitazone may have higher risks than pioglitazone. 最近的汇总分析进一步表明罗格列酮与匹格列酮相比可能会导致更高的风险。
- Beginning in 1999, rosiglitazone maleate and pioglitazone hydrochloride were approved for use. 从1999年开始，马来酸罗格列酮和盐酸匹格列酮被批准使用。
- As one of insulin sensitizing agents, rosiglitazone is mainly used to cure type 2 diabetes mellitus. 国外十余年的临床应用发现，罗格列酮可明显改善2型糖尿病病人的血脂紊乱，延缓动脉粥样硬化病变进展。
- Aandia is known generically as rosiglitazone, while Actos is known as pioglitazone. 文迪雅的通用名为罗格列酮，艾可拓通用名为吡格列酮。
- On the other hand, there isthe suspicion that rosiglitazone maybe is，it has a problem. 此外，也怀疑罗格列酮可能与心脏疾病有关，但是还不确定。
- The phosphorylation of Akt and FAK were dramatically attenuated in cells treated with rosiglitazone. 由于FAK和Akt都是抑癌基因PTEN（phosphatase and tensin homolog deleted on chromosome ten）的下游信号分子，因此我们检测了ROS对PTEN的影响，结果发现ROS可以上调PTEN蛋白质，而且这种上调作用具有剂量和时间依赖性；
- Results The results showed that rosiglitazone reduced FPG, TG, CRP, and HbA1 c levels respectively. 结果治疗后空腹血糖、糖化血红蛋白、血TG、C反应蛋白水平较治疗前有显著下降，胰岛素敏感性明显上升。
- Rosiglitazone and pioglitazone are part of a group of drugs called thiazolidinediones. 罗格列酮和吡咯列酮同属噻唑烷二酮类。
- This article explains the mechanism and clinical efficacy of rosiglitazone in treating type 2 diabetes mellitus. 罗格列酮则能显著降低胰岛素抵抗并改善B细胞功能,从而持久稳定地控制糖尿病。
- They all had started treatment with either rosiglitazone or pioglitazone between April 2002 and March 2008. 他们是在2002年4月到2008年3月开始使用罗格列酮或吡咯列酮的。
- When rosiglitazone was first authorised in the EU in 2000, it was contraindicated in patients with a history of cardiac failure. 2000年欧盟首次批准使用罗格列酮时，就其应用于心衰病史患者身上就存在着争议。
